SHANGHAI – China's startup biotech scene has gained a new entrant: Transthera Biosciences Co. Ltd., of Nanjing, Jiangsu. Transthera has received $10 million, from a group of investors led by Morningside Ventures, to discover and develop new chemical entities (NCEs) for oncology, cardiovascular diseases and other indications.